[go: up one dir, main page]

WO2021225963A3 - Methods and compositions for induction of antitumor immunity - Google Patents

Methods and compositions for induction of antitumor immunity Download PDF

Info

Publication number
WO2021225963A3
WO2021225963A3 PCT/US2021/030478 US2021030478W WO2021225963A3 WO 2021225963 A3 WO2021225963 A3 WO 2021225963A3 US 2021030478 W US2021030478 W US 2021030478W WO 2021225963 A3 WO2021225963 A3 WO 2021225963A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
induction
antitumor immunity
prmt5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/030478
Other languages
French (fr)
Other versions
WO2021225963A2 (en
Inventor
Ze'ev A. Ronai
Hyungsoo KIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Priority to US17/997,757 priority Critical patent/US20230301998A1/en
Publication of WO2021225963A2 publication Critical patent/WO2021225963A2/en
Publication of WO2021225963A3 publication Critical patent/WO2021225963A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are methods and compositions for diagnosing, treating, or ameliorating symptoms of cancer, including melanoma, with inhibitors of PRMT5 and immune response regulators in combination with checkpoint inhibitor therapy.
PCT/US2021/030478 2020-05-04 2021-05-03 Methods and compositions for induction of antitumor immunity Ceased WO2021225963A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/997,757 US20230301998A1 (en) 2020-05-04 2021-05-03 Methods and compositions for induction of antitumor immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019914P 2020-05-04 2020-05-04
US63/019,914 2020-05-04

Publications (2)

Publication Number Publication Date
WO2021225963A2 WO2021225963A2 (en) 2021-11-11
WO2021225963A3 true WO2021225963A3 (en) 2021-12-09

Family

ID=78468730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/030478 Ceased WO2021225963A2 (en) 2020-05-04 2021-05-03 Methods and compositions for induction of antitumor immunity

Country Status (2)

Country Link
US (1) US20230301998A1 (en)
WO (1) WO2021225963A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162314A1 (en) * 2024-02-02 2025-08-07 上海湃隆生物科技有限公司 Pharmaceutical composition containing prmt5 inhibitor and pd-1/pd-l1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145150A2 (en) * 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
WO2018100535A1 (en) * 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089883A1 (en) * 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145150A2 (en) * 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
WO2018100535A1 (en) * 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEDORIW ANDREW; RAJAPURKAR SATYAJIT R; O'BRIEN SHANE; GERHART SARAH V; MITCHELL LORNA H; ADAMS NICHOLAS D; RIOUX NATHALIE; LINGARA: "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss", CANCER CELL, CELL PRESS, US, vol. 36, no. 1, 8 July 2019 (2019-07-08), US , pages 100, XP085734589, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2019.05.014 *
SNYDER KATIRI J., ZITZER NINA C., GAO YANDI, CHOE HANNAH K., SELL NATALIE E., NEIDEMIRE-COLLEY LOTUS, IGNACI ANORA, KALE CHARUTA, : "PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease", JCI INSIGHT, vol. 5, no. 8, 23 April 2020 (2020-04-23), pages 1 - 20, XP055879535, ISSN: 2379-3708, DOI: 10.1172/jci.insight.131099 *

Also Published As

Publication number Publication date
US20230301998A1 (en) 2023-09-28
WO2021225963A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2023006766A (en) Shp2 inhibitor compositions and methods for treating cancer.
MX2025004367A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
WO2019016772A3 (en) Compositions and methods to treat cancer
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2023015298A (en) Erk1/2 and shp2 inhibitors combination therapy.
NZ780203A (en) Genetically modified immune cell, preparation method therefor, and application
MX2023013912A (en) Methods for inhibiting ras.
MX2024011278A (en) Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer.
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
MX2021007350A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2022004577A (en) Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors.
WO2021225963A3 (en) Methods and compositions for induction of antitumor immunity
WO2021202755A3 (en) Biomarker panels for stratification of response to immune checkpoint blockade in cancer
MX2024010878A (en) Preventive treatment of migraine.
IL291625A (en) Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and/or tyrosine kinase inhibitors and markers of responsiveness to such
WO2019140372A3 (en) Methods of treatment by inhibition of bfl 1
BR112022007179A2 (en) TIM-3 INHIBITORS AND USES THEREOF
MY208979A (en) Method of treating tumours
WO2020092720A3 (en) Methods of treating cancer with farnesyltransferase inhibitors
MX2023006882A (en) Cancer treatment using bosentan in combination with a checkpoint inhibitor.
MX2020009478A (en) Compounds and uses thereof to treat tumors in a subject.
MX2025001050A (en) Combination therapy of cdk7 inhibitors with other anti-cancer therapies
WO2024108114A3 (en) Methods of selecting cancer patients amendable to treatment with immune checkpoint inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21799876

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21799876

Country of ref document: EP

Kind code of ref document: A2